You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Custom Fit 3D-Printed Pediatric Respiratory Masks

    SBC: ADVANCED MEDICAL ELECTRONICS CORP            Topic: NICHD

    DESCRIPTION provided by applicant This project will develop an FDA approved process D printing system and advanced D printable material suitable for point of care manufacturing of custom fit continuous positive airway pressure CPAP masks for neonates In extremely low birth weight infants nasal CPAP therapy is delivered via soft biocompatible neonatal sized nasal masks suitable for lon ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. A Low Cost, Quantitative, Chemical Specific Device for Illicit Drug Detection

    SBC: MKS Technology            Topic: NIDA

    DESCRIPTION provided by applicant This proposal will assess the quantitative capabilities of surface enhanced Raman scattering SERS detection of cocaine and marijuana metabolites in urine samples Combining low cost instrumentation and novel chemical sensing provides an innovative new approach for diagnosing illicit drug use Current methods use a colorimetric indicator to screen specimens fo ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Live-Cell Fluorescence Lifetime FRET Assays for HTS

    SBC: Fluorescence Innovations, Inc.            Topic: R42

    DESCRIPTION provided by applicant We seek to develop and commercialize a powerful technology platform to increase dramatically the effectiveness of drug discovery using high throughput screening HTS based on fluorescence lifetime FLT readouts of FRET in live cells This breakthrough is enabled by a combination of two complementary and synergistic technologies fluorescent biosensor engineer ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Distance Filtering System for Retinal Implants

    SBC: ADVANCED MEDICAL ELECTRONICS CORP            Topic: N

    DESCRIPTION provided by applicant We propose to develop and evaluate the utility of a novel input camera system for retinal prosthetics that allows users to filter optical imagery based on distance from the observer We call this andquot depth filteringandquot which can be accomplished with a depth sensing stereoscopic camera system Retinal prostheses can restore partial vision to people bli ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Reduced gluten cereal grains

    SBC: Arcadia Biosciences, Inc.            Topic: 300

    DESCRIPTION provided by applicant Celiac disease CD is the most common food sensitive enteropathy known affecting approximately of the population and its incidence appears to be on the rise In addition non celiac gluten sensitivity GS has recently been revealed to be a distinct condition that affects a growing number of individuals Both of these conditions are triggered by gluten a ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Directed Antifungal Therapy for HIV-associated Cryptococcal Meningitis

    SBC: Minnetronix Medical, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Directed Antifungal Therapy for HIV associated Cryptococcal Meningitis PI Lad Shivanand and McCabe Aaron Project Summary Cryptococcosis is an important systemic mycosis and one of the most prevalent infectious diseases in human immunodeficiency virus HIV positive individuals Amongst the million people with HIV AIDS recent estimates indicate that there ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Novel Therapeutic Approach for Cryptococcal Meningitis

    SBC: Minnetronix Medical, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant When Cryptococcus is manifested as Cryptococcal meningitis CM it creates a large burden of mortality and morbidity to the patient and is very difficult for the clinician to treat There are now US cases and over million cases of CM worldwide annually with estimated deaths of per year CM is caused when Cryptococcus neoformans a basidiomyce ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Synactix Pharmaceuticals I-Corps Application

    SBC: SYNACTIX PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Polypharmacology represents a new and attractive approach to treat malignances as lasting and robust efficacy could be obtained through the inhibition of multiple survival pathways with one therapeutic agent In line with this method we have designed a RET rearranged during transfection VEGFR vascular endothelial growth factor receptor small molecule ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Pre-IND study of PMT-254, a pan-FLT3 inhibitor for the treatment of FLT3 driven cancers.

    SBC: PROMUTECH PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Pathological activating mutations in the FLT kinase represent the most common genetic alteration in patients with acute myeloid leukemia AML occurring in approximately one third of cases Recently we performed translational studies that identified drug resistant kinase domain mutations in FLT ITD at the time of relapse in AML patients treated with the FLT ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Extraction and Characterization of a Safer, Cost-effective Anti-inflammatory

    SBC: Botanisol LLC            Topic: R

    DESCRIPTION provided by applicant Inflammatory disease states are leading causes of death and disability and a major cost to healthcare in the United States There is an epidemic of death and hospitalizations due to adverse effects from NSAIDs TAI LCx Turmeric Anti Inflammatory Lipophilic Component X is a novel anti inflammatory discovered in previously unrecognized pharmacologically activ ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government